Business Wire, 4/12/2010
Derma Sciences, Inc. (NASDAQ: DSCI), a specialty medical device/pharmaceutical company is poised to take advantage of the tremendous growth opportunity in wound care based on their distinct competitive advantage resulting from their worldwide, perpetual, exclusive license for the distribution of MEDIHONEY®. MEDIHONEY® is made from Leptospermum (manuka) honey, indigenous to New Zealand and Australia which has been shown to be very effective in a variety of advanced wound care indications.
Comvita New Zealand, from whom Derma has secured this license, controls approximately 75% of worldwide production and owns key intellectual property and patents concerning its use in medical dressings. This license gives Derma control over three-quarters of the global market for manuka-based dressings…
No comments:
Post a Comment